The PE Ratio as of November 2024 (TTM) for Protalix BioTherapeutics, Inc. (PLX) is -11.27

According to Protalix BioTherapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -11.27. This represents a change of 215.78% compared to the average of -3.57 of the last 4 quarters.

Protalix BioTherapeutics, Inc. (PLX) Historical PE Ratio (quarterly & annually)

How has PLX PE Ratio performed in the past?

The mean historical PE Ratio of Protalix BioTherapeutics, Inc. over the last ten years is -5.85. The current -11.27 PE Ratio has changed 19.15% with respect to the historical average. Over the past ten years (40 quarters), PLX's PE Ratio was at its highest in in the December 2020 quarter at 75.12. The PE Ratio was at its lowest in in the June 2015 quarter at -90.02.

Protalix BioTherapeutics, Inc. (PLX) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Protalix BioTherapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Protalix BioTherapeutics, Inc. (PLX) Average PE Ratio

How has PLX PE Ratio performed in the past?

The current PE Ratio of Protalix BioTherapeutics, Inc. (PLX) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Protalix BioTherapeutics, Inc. (PLX) PE Ratio vs. Peers

How is PLX’s PE Ratio compared to its peers?

Protalix BioTherapeutics, Inc.’s PE Ratio is less than Corvus Pharmaceuticals, Inc. (-10.50), less than Aldeyra Therapeutics, Inc. (-6.45), less than Gamida Cell Ltd. (-0.23), less than Checkpoint Therapeutics, Inc. (-3.48), less than Cidara Therapeutics, Inc. (-1.10), less than Akebia Therapeutics, Inc. (-8.60), less than X4 Pharmaceuticals, Inc. (-4.05), less than Seres Therapeutics, Inc. (-4.61), less than eFFECTOR Therapeutics, Inc. (-0.00), less than PDS Biotechnology Corporation (-1.90), less than aTyr Pharma, Inc. (-2.33), less than Elevation Oncology, Inc. (-0.85), less than Lexicon Pharmaceuticals, Inc. (0), less than Iovance Biotherapeutics, Inc. (-1.45), less than ImmunoGen, Inc. (-6.32), less than null (322.18),

Build a custom stock screener for Protalix BioTherapeutics, Inc. (PLX) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Protalix BioTherapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Protalix BioTherapeutics, Inc. (PLX) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Protalix BioTherapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.